In addition to their antidiabetic effects, GLP-1R agonists have shown substantial benefits in promoting weight loss, largely through appetite suppression and delayed gastric emptying
Semaglutide injections and dulaglutide (Trulicity) are administered once weekly
If the patient has both obesity and type 2 diabetes, the provider may be able to prescribe Ozempic for the diabetes indication, and the patient may experience weight loss as a secondary benefit
These molecules circulate throughout the body and directly trigger inflammatory responses in joints, worsening osteoarthritis and rheumatoid arthritis symptoms
Individuals using for diabetes management tend to stay on the drugs longer, with 51% of current users having used them for a year or more
Meier JJ, Gallwitz B, Siepmann N, et al